目的 探討蒲地藍(lán)消炎片聯(lián)合布地奈德治療小兒急性喉炎的療效。方法 按隨機(jī)數(shù)字表法將2021年1月—2023年12月九〇三醫(yī)院收治的100例急性喉炎患兒分為對(duì)照組（50例）和治療組（50例）。對(duì)照組給予吸入用布地奈德混懸液，1 g/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服蒲地藍(lán)消炎片，2～3片/次，4次/d。兩組患兒均持續(xù)治療5 d。觀察兩組患兒臨床療效，比較治療前后兩組患兒癥狀改善時(shí)間、喉鏡下體征評(píng)分及超敏C反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-10（IL-10）及白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，對(duì)照組與治療組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（84.00% vs 96.00%，P＜0.05）。治療后，與對(duì)照組比較，治療組的癥狀改善時(shí)間均明顯縮短（P＜0.05）。治療后，兩組患兒會(huì)厭充血、黏液附著、水腫、聲帶充血評(píng)分明顯低于治療前（P＜0.05），且治療組患兒喉鏡下體征評(píng)分明顯低于對(duì)照組（P＜0.05）。治療后，兩組hs-CRP、IL-10和IL-6水平明顯低于治療前（P＜0.05），且治療組治療后hs-CRP、IL-10和IL-6水平明顯低于對(duì)照組（P＜0.05）。結(jié)論 蒲地藍(lán)消炎片聯(lián)合布地奈德治療小兒急性喉炎療效及安全性均較高，能減輕患兒炎性反應(yīng)，改善喉部癥狀。

Objective To explore the clinical effect of Pudilan Xiaoyan Tablets combined with budesonide in treatment of acute laryngitis in children. Methods Children (100 cases) with acute laryngitis in 903 Hospital from January 2021 to December 2023 were divided into control group (50 cases) and treatment group (50 cases) according to random number table method,. Children in the control group were treated with Budesonide Suspension for inhalation, 1 g/time, twice daily. Patients in the control group were po administered with Pudilan Xiaoyan Tablets, 2—3 tablets/time, four times daily. Children in two groups were treated for 5 d. After treatment, the clinical effects were evaluated, the symptom improvement time, scores of signs under laryngoscope and hs-CRP, IL-10 and IL-6 in two groups were compared before and after treatment. Results After treatment, the total effective rates in the control and treatment groups were 84.00% vs 96.00%, respectively, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the symptom improvement time in the treatment group was shorter than that in the control group (P < 0.05). After treatment, the scores of epiglottic congestion, mucus adhesion, edema, vocal cord congestion and other laryngoscopic signs in two groups were significantly decreased (P < 0.05), and the scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of hs-CRP, IL-10 and IL-6 in two groups were significantly decreased (P < 0.05), and the levels in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Pudilan Xiaoyan Tablets combined with budesonide in treatment of acute laryngitis in children has high efficacy and safety in the treatment of acute laryngitis, which can alleviate the inflammatory reaction of patients and improve laryngeal symptoms.

R985

四川省科學(xué)技術(shù)研究發(fā)展計(jì)劃項(xiàng)目（2019YJ0057）